M&T Bank Corp Buys New Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

M&T Bank Corp bought a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 16,699 shares of the medical instruments supplier's stock, valued at approximately $1,551,000. M&T Bank Corp owned approximately 0.07% of LeMaitre Vascular at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in LMAT. Townsquare Capital LLC boosted its stake in LeMaitre Vascular by 38.0% in the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock worth $4,454,000 after purchasing an additional 13,210 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of LeMaitre Vascular by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after buying an additional 11,395 shares during the period. Nicholas Investment Partners LP purchased a new position in shares of LeMaitre Vascular during the second quarter valued at $3,900,000. Creative Planning raised its position in LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier's stock valued at $334,000 after buying an additional 617 shares during the period. Finally, Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock worth $108,068,000 after acquiring an additional 11,318 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on LMAT. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday. JMP Securities boosted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a report on Tuesday, August 20th. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective for the company. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $94.57.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded up $0.41 during midday trading on Friday, reaching $100.69. 183,716 shares of the company's stock traded hands, compared to its average volume of 124,557. LeMaitre Vascular, Inc. has a 52 week low of $52.88 and a 52 week high of $109.58. The company's 50 day simple moving average is $97.65 and its 200 day simple moving average is $89.54. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 55.02, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's revenue was up 15.6% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. As a group, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.64%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

Insider Activity

In related news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company's stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.